This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Pfaller, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Pfaller, M. A.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2003, p. 3623-3626, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3623-3626.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi

D. J. Diekema,1,2* S. A. Messer,2 R. J. Hollis,2 R. N. Jones,3,4 and M. A. Pfaller2,5

Department of Internal Medicine,1 Department of Pathology, University of Iowa College of Medicine,2 Department of Epidemiology, University of Iowa College of Public Health, Iowa City,5 Jones Microbiology Institute, North Liberty, Iowa,3 Tufts University School of Medicine, Boston, Massachusetts4

Received 2 April 2003/ Returned for modification 23 April 2003/ Accepted 6 May 2003

We examined the in vitro activity of caspofungin, posaconazole, voriconazole, ravuconazole, itraconazole, and amphotericin B against 448 recent clinical mold isolates. The endpoint for reading caspofungin was the minimum effective concentration (MEC). Among the triazoles, posaconazole was most active, inhibiting 95% of isolates at <=1 µg/ml, followed by ravuconazole (91%), voriconazole (90%), and itraconazole (79%). Caspofungin and amphotericin B inhibited 93% and 89% of isolates at <=1 µg/ml, respectively, with caspofungin demonstrating an MEC 90 of 0.12 µg/ml. All three new triazoles and caspofungin inhibited >95% of Aspergillus spp. at <=1 µg/ml compared to 83% for itraconazole and 91% for amphotericin B. Amphotericin B inhibited only 38% of Aspergillus terreus isolates at <=1 µg/ml, whereas the three new triazoles and caspofungin inhibited all A. terreus at <=0.5 µg/ml. The new triazoles and caspofungin have excellent in vitro activity against a very large collection of recent clinical isolates of Aspergillus spp., and some in vitro activity against selected other filamentous fungi.

* Corresponding author. Mailing address: C606 GH, University of Iowa College of Medicine, 200 Hawkins Dr., Iowa City, IA 52242. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: daniel-diekema{at}uiowa.edu.

Journal of Clinical Microbiology, August 2003, p. 3623-3626, Vol. 41, No. 8
0095-1137/03/$08.00+0     DOI: 10.1128/JCM.41.8.3623-3626.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., Johnson, E. M., Knapp, C. C., Motyl, M. R., Ostrosky-Zeichner, L., Sheehan, D. J., Walsh, T. J., for the Clinical and Laboratory Standards Institut, (2009). Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 47: 3142-3146 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Kroeger, J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2009). In Vitro Susceptibility of Clinical Isolates of Aspergillus spp. to Anidulafungin, Caspofungin, and Micafungin: a Head-to-Head Comparison Using the CLSI M38-A2 Broth Microdilution Method. J. Clin. Microbiol. 47: 3323-3325 [Abstract] [Full Text]  
  • Conte, J. E. Jr., Golden, J. A., Krishna, G., McIver, M., Little, E., Zurlinden, E. (2009). Intrapulmonary Pharmacokinetics and Pharmacodynamics of Posaconazole at Steady State in Healthy Subjects. Antimicrob. Agents Chemother. 53: 703-707 [Abstract] [Full Text]  
  • Rachwalski, E. J, Wieczorkiewicz, J. T, Scheetz, M. H (2008). Posaconazole: An Oral Triazole with an Extended Spectrum of Activity. The Annals of Pharmacotherapy 42: 1429-1438 [Abstract] [Full Text]  
  • Simitsopoulou, M., Roilides, E., Paliogianni, F., Likartsis, C., Ioannidis, J., Kanellou, K., Walsh, T. J. (2008). Immunomodulatory Effects of Voriconazole on Monocytes Challenged with Aspergillus fumigatus: Differential Role of Toll-Like Receptors. Antimicrob. Agents Chemother. 52: 3301-3306 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Rice, C., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). In Vitro Survey of Triazole Cross-Resistance among More than 700 Clinical Isolates of Aspergillus Species. J. Clin. Microbiol. 46: 2568-2572 [Abstract] [Full Text]  
  • de la Escalera, C. M., Aller, A. I., Lopez-Oviedo, E., Romero, A., Martos, A. I., Canton, E., Peman, J., Martos, P. G., Martin-Mazuelos, E. (2008). Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 61: 1083-1086 [Abstract] [Full Text]  
  • Garcia-Effron, G., Dilger, A., Alcazar-Fuoli, L., Park, S., Mellado, E., Perlin, D. S. (2008). Rapid Detection of Triazole Antifungal Resistance in Aspergillus fumigatus. J. Clin. Microbiol. 46: 1200-1206 [Abstract] [Full Text]  
  • Espinel-Ingroff, A., Johnson, E., Hockey, H., Troke, P. (2008). Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 61: 616-620 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Boyken, L., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2008). Selection of a Surrogate Agent (Fluconazole or Voriconazole) for Initial Susceptibility Testing of Posaconazole against Candida spp.: Results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46: 551-559 [Abstract] [Full Text]  
  • Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007). In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents. Antimicrob. Agents Chemother. 51: 2587-2590 [Abstract] [Full Text]  
  • Hedayati, M. T., Pasqualotto, A. C., Warn, P. A., Bowyer, P., Denning, D. W. (2007). Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology 153: 1677-1692 [Abstract] [Full Text]  
  • Smith, P. J., Olson, J. A., Constable, D., Schwartz, J., Proffitt, R. T., Adler-Moore, J. P. (2007). Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother 59: 941-951 [Abstract] [Full Text]  
  • Krishna, G., Sansone-Parsons, A., Martinho, M., Kantesaria, B., Pedicone, L. (2007). Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection. Antimicrob. Agents Chemother. 51: 812-818 [Abstract] [Full Text]  
  • Simitsopoulou, M., Roilides, E., Likartsis, C., Ioannidis, J., Orfanou, A., Paliogianni, F., Walsh, T. J. (2007). Expression of Immunomodulatory Genes in Human Monocytes Induced by Voriconazole in the Presence of Aspergillus fumigatus. Antimicrob. Agents Chemother. 51: 1048-1054 [Abstract] [Full Text]  
  • Perkhofer, S., Lugger, H., Dierich, M. P., Lass-Florl, C. (2007). Posaconazole Enhances the Activity of Amphotericin B against Aspergillus Hyphae In Vitro. Antimicrob. Agents Chemother. 51: 791-793 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  
  • Spellberg, B., Schwartz, J., Fu, Y., Avanesian, V., Adler-Moore, J., Edwards, J. E. Jr, Ibrahim, A. S. (2006). Comparison of antifungal treatments for murine fusariosis. J Antimicrob Chemother 58: 973-979 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (2006). Comparison of Three Commercial Assays and a Modified Disk Diffusion Assay with Two Broth Microdilution Reference Assays for Testing Zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with Posaconazole and Amphotericin B. J. Clin. Microbiol. 44: 3616-3622 [Abstract] [Full Text]  
  • Enoch, D. A., Ludlam, H. A., Brown, N. M. (2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol 55: 809-818 [Abstract] [Full Text]  
  • Balashov, S. V., Park, S., Perlin, D. S. (2006). Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1.. Antimicrob. Agents Chemother. 50: 2058-2063 [Abstract] [Full Text]  
  • Kahn, J. N., Hsu, M.-J., Racine, F., Giacobbe, R., Motyl, M. (2006). Caspofungin Susceptibility in Aspergillus and Non-Aspergillus Molds: Inhibition of Glucan Synthase and Reduction of {beta}-D-1,3 Glucan Levels in Culture.. Antimicrob. Agents Chemother. 50: 2214-2216 [Abstract] [Full Text]  
  • Sansone-Parsons, A., Krishna, G., Calzetta, A., Wexler, D., Kantesaria, B., Rosenberg, M. A., Saltzman, M. A. (2006). Effect of a Nutritional Supplement on Posaconazole Pharmacokinetics following Oral Administration to Healthy Volunteers.. Antimicrob. Agents Chemother. 50: 1881-1883 [Abstract] [Full Text]  
  • Messer, S. A., Jones, R. N., Fritsche, T. R. (2006). International Surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003).. J. Clin. Microbiol. 44: 1782-1787 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., Rodriguez-Tudela, J. L. (2006). Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi. Antimicrob. Agents Chemother. 50: 917-921 [Abstract] [Full Text]  
  • Ullmann, A. J., Cornely, O. A., Burchardt, A., Hachem, R., Kontoyiannis, D. P., Topelt, K., Courtney, R., Wexler, D., Krishna, G., Martinho, M., Corcoran, G., Raad, I. (2006). Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.. Antimicrob. Agents Chemother. 50: 658-666 [Abstract] [Full Text]  
  • Antachopoulos, C., Meletiadis, J., Roilides, E., Sein, T., Walsh, T. J. (2006). Rapid Susceptibility Testing of Medically Important Zygomycetes by XTT Assay. J. Clin. Microbiol. 44: 553-560 [Abstract] [Full Text]  
  • Yan, J.-H., Marino, M. R., Smith, R. A., Kanamaluru, V., O'Mara, E. M., Grasela, D. M. (2006). The Effect of Ravuconazole on the Pharmacokinetics of Nelfinavir in Healthy Male Volunteers. J Clin Pharmacol 46: 193-200 [Abstract] [Full Text]  
  • Brown, J. (2005). Zygomycosis: An emerging fungal infection. Am J Health Syst Pharm 62: 2593-2596 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Monzon, A., Rodriguez-Tudela, J. L. (2005). In Vitro Activity of Ravuconazole against 923 Clinical Isolates of Nondermatophyte Filamentous Fungi. Antimicrob. Agents Chemother. 49: 5136-5138 [Abstract] [Full Text]  
  • Bialek, R, Konrad, F, Kern, J, Aepinus, C, Cecenas, L, Gonzalez, G M, Just-Nubling, G, Willinger, B, Presterl, E, Lass-Florl, C, Rickerts, V (2005). PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 58: 1180-1184 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Messer, S. A., Tendolkar, S., Hollis, R. J., Diekema, D. J. (2005). Comparison of Results of Voriconazole Disk Diffusion Testing for Candida Species with Results from a Central Reference Laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43: 5208-5213 [Abstract] [Full Text]  
  • Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., Flattery, A., Gill, C., Chrebet, G., Parent, S. A., Kurtz, M., Teppler, H., Douglas, C. M., Perlin, D. S. (2005). Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates. Antimicrob. Agents Chemother. 49: 3264-3273 [Abstract] [Full Text]  
  • Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  
  • Spellberg, B., Edwards, J. Jr., Ibrahim, A. (2005). Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management. Clin. Microbiol. Rev. 18: 556-569 [Abstract] [Full Text]  
  • Golan, Y. (2005). Overview of transplant mycology. Am J Health Syst Pharm 62: S17-S21 [Abstract] [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Garcia-Effron, G., Alcazar-Fuoli, L., Mellado, E., Buitrago, M. J., Rodriguez-Tudela, J. L. (2005). Combined Activity In Vitro of Caspofungin, Amphotericin B, and Azole Agents against Itraconazole-Resistant Clinical Isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 1232-1235 [Abstract] [Full Text]  
  • Palanisamy, A., Chao, S. D., Fouts, M., Kerr, D. (2005). Central nervous system aspergillosis in an immunocompetent patient: Cure in a hospice setting with very high-dose itraconazole. AM J HOSP PALLIAT CARE 22: 139-144 [Abstract]  
  • Mukherjee, P. K., Sheehan, D. J., Hitchcock, C. A., Ghannoum, M. A. (2005). Combination Treatment of Invasive Fungal Infections. Clin. Microbiol. Rev. 18: 163-194 [Abstract] [Full Text]  
  • Simitsopoulou, M., Gil-Lamaignere, C., Avramidis, N., Maloukou, A., Lekkas, S., Havlova, E., Kourounaki, L., Loebenberg, D., Roilides, E. (2004). Antifungal Activities of Posaconazole and Granulocyte-Macrophage Colony-Stimulating Factor Ex Vivo and in Mice with Disseminated Infection Due to Scedosporium prolificans. Antimicrob. Agents Chemother. 48: 3801-3805 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2004). Rare and Emerging Opportunistic Fungal Pathogens: Concern for Resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42: 4419-4431 [Full Text]  
  • Steinbach, W. J., Perfect, J. R., Schell, W. A., Walsh, T. J., Benjamin, D. K. Jr. (2004). In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection. Antimicrob. Agents Chemother. 48: 3217-3225 [Full Text]  
  • Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Garcia-Effron, G., Rodriguez-Tudela, J. L. (2004). In Vitro Activities of Ravuconazole and Four Other Antifungal Agents against Fluconazole-Resistant or -Susceptible Clinical Yeast Isolates. Antimicrob. Agents Chemother. 48: 3107-3111 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Lyman, C. A., Groll, A. H., Mickiene, D., Peter, J., Bacher, J., Roussillon, K., Hemmings, M., Armstrong, D., Avila, N. A., Walsh, T. J. (2004). Efficacy, Safety, and Plasma Pharmacokinetics of Escalating Dosages of Intravenously Administered Ravuconazole Lysine Phosphoester for Treatment of Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother. 48: 1188-1196 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»